



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify under 37 C.F.R. 1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Label No. EV 238067149 US with sufficient postage on the date indicated below and in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

[X] If checked, two copies of this correspondence are enclosed.

Date of Deposit:

9/10/2004

Signature

Dawn M. Janelle

Printed name of person mailing correspondence

Applicant: DUNMORE, Simon Jon et al.

Art Unit: 1641

Serial No.: 10/753,717

Examiner: Unknown

Filed: 01/08/2004

Title: INHIBITION OF AMYLIN RELEASE

**INFORMATION DISCLOSURE STATEMENT AND AUTHORIZATION TO
CHARGE DEPOSIT ACCOUNT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

[] under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

[X] under 37 CFR 1.97(b), or

(Whichever occurs last of the following: within three months of filing national application; within three months of date of entry of the national stage in international application; before the mailing date of first office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination)

[] under 37 CFR 1.97(c) together with either:

[] a Statement under 37 CFR 1.97(e), as checked below, or

[] a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

[] under 37 CFR 1.97(d) together with:

[] a Statement under 37 CFR 1.97(e), as checked below, and

[] a Petition under 37 CFR 1.97(d)(2), and

[] a \$130.00 petition fee set forth in 37 CFR 1.17(i).

(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

[] Applicant requests that the attached IDS and cited reference(s) [] be placed in the application filewrapper.

(Filed after payment of issue fee)

[] Some of the listed references were cited in a European Search Report in a counterpart European application or cited in a communication from a foreign patent office in a counterpart foreign application.

- ☒ Enclosed herewith is form PTO-1449 (reproduced form; 2 pages), with a copy of the S reference noted thereon.
- ☒ With the exception of Reference S, copies of the reference(s) noted on the enclosed form PTO/SB/08 were previously cited by or submitted to the Patent and Trademark Office in connection with U.S. Application Serial No. [08/961,968 and 08/440,061], from which the present application claims benefit under 35 U.S.C. § 120 (37 C.F.R. 1.98(d)).

It is requested that the information disclosed herein be made of record in this application, and that the references listed on the enclosed form PTO-1449 appear under the "References Cited" heading of any Patent which issues from this application, (MPEP 1302.12).

Concise Explanation Requirement (non-English references):

- ☐ The "concise explanation" requirement for reference(s) [AD, AK] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ the enclosed English language abstracts.

Statement Under 37 CFR 1.97(e):

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.
- ☒ No fee is believed to be due for this submission. However Applicant(s) hereby authorize the Commissioner to charge any fees that may be deemed to be due or to credit any overpayment to Deposit Account No. 50-0590. Two copies of this Statement are enclosed.
- ☒ The Commissioner is hereby authorized to charge any deficiency in fees and credit any overpayment to Deposit Account 50-0590. Two copies of this Statement are enclosed.

Respectfully submitted,
BIOMEASURE, INCORPORATED

Dated: Sept 10, 2004

By Pamela C. Ball
Pamela C. Ball, Agent for Applicant(s)
Registration No.: 53,963

27 Maple Street
Milford, Massachusetts 01757
Phone: (508)478-0144
Facsimile: (508) 473-3531

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
043B/APPLICATION NO.
10/753,717INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

APPLICANT
Simon Jon Dunmore, et al.FILING DATE
January 8, 2004GROUP/EXAMINER
1641

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A	5,260,275	11/1993	Cooper, et al.	514	12	
	B	5,234,906	08/1993	Young, et al.	514	12	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	C	WO 93/13130	07/08/93	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	D	Davenport et al., "Somatostatin Type 5 Receptors Mediate the Inhibitory Action of Somatostatin on Insulin Secretion in Zucker Fatty Rat Perfused Pancreas", Diabetologia (Supp. 1) 38(1995):A106, XP000602793.					
	E	Moldovan et al., "Somatostatin Inhibits B-Cell Secretion via a Subtype-2 Somatostatin Receptor in the Isolated Perfused Human Pancreas", J. of Surgical Research 59(1995):85-90, XP000602793.					
	F	Mitsukawa et al., "Islet Amyloid Polypeptide Response to Glucose, Insulin, and Somatostatin Analogue Administration", Diabetes 39(1990):639-642.					

EXAMINER

DATE CONSIDERED

G	Rudinger, "Peptide Hormones", ed. J.A. Parsons (University Park Press Baltimore 1976). 1-7.
H	Hoyer, et al., "Molecular Pharmacology of Somatostatin Receptors", Naunyn-Schmiedeberg's Arch Pharmacology 350(1994):441-453.
I	Inoue, et al., "Effects of Exogenous Somatostatin and Insulin on Islet Amyloid Polypeptide (Amylin) Release from Perfused Rat Pancreas", Horm. Metab. Res. 24(1992):251-253
J	Moore, et al., "Co-Secretion of Amylin and Insulin from Cultured Islet Beta-Cells: Modulation By Nutrient Secretagogues, Islet Hormones & Hypoglycemic Agents", Biochemical & Biophysical Res. Commun. 179(1991):1-9.
K	Rossowski, et al., "Specific Inhibition of Rat Pancreatic Insulin or Glucagon Release by Receptor-Selective Somatostatin Analogs", Biochemical & Biophysical Res. Commun. 179(1994):341-346.
L	Raynor, et al., "Cloned Somatostatin Receptors: Identification of Subtype-Selective Peptides and Demonstration of High Affinity Binding of Linear Peptides", Molecular Pharmacology 43:838-844.
M	Guidobono, et al., "Amylin Given by Central and Peripheral Routes Inhibits Acid Gastric Secretion", Peptides 15(1994):699-702.
N	Peiro, et al., "Inhibition of Insulin Release by Amylin is not Mediated by Changes in Somatostatin Output", Life Sciences 49(1991):761-765.
O	Yamada, et al., "Cloning, Functional Expression and Pharmacological Characterization of a Fourth (hSSTR4) and a Fifth (hSSTR5) Human Somatostatin Receptor Subtype", Birham Biophys Res. Commun. 195(1993):844-852.
P	Ohtsuka, et al., "Amylin-Containing Cells in the Gastro-Entero-Pancreatic (GEP) Endocrine System of the Rat and Humans", Acta Histochem. Cytochem, Vol. 26, No. 5(1993):405-414.
Q	Tokuyama, et al., "Evolution of B-Cell Dysfunction in the Male Zucker Diabetic Fatty Rat", Diabetes 44(1995):1447-1457.
R	Dunmore, et al., "Beta-Cell Tropin- and Glucose-Induced Hypersecretion of Insulin and Amylin from Perfused Fatty Rat Pancreas", J. Endocrinology, 137(1993):375-381.
S	O'Carroll et al., "Molecular Cloning and Expression of a Pituitary Somatostatin Receptor with Preferential Affinity for Somatostatin-28", Molecular Pharmacology 42(1992):939-946.

EXAMINER

DATE CONSIDERED